中国药业2026，Vol.35Issue(6)：34-37,4.DOI:10.3969/j.issn.1006-4931.2026.06.008
肿瘤临床药师参与免疫检查点抑制剂全流程药学服务实践
Practice of Oncology Clinical Pharmacists' Participating in the Full-Process Pharmaceutical Care for Immune Checkpoint Inhibitors
摘要
Abstract
Objective To provide more precise and safe pharmaceutical services for tumor patients treated with immune checkpoint inhibitors(ICIs).Methods A total of 170 patients treated with ICIs from January 1,2023 to June 30,2024 in the hospital were selected and randomly divided into the control group and the observation group,with 85 cases in each group.Both groups were given full-process pharmaceutical care for the use of ICIs,including assessment and selection,pharmaceutical care,and quality control management.However,only the observation group had the participation of oncology clinical pharmacists.The incidence of immune-related adverse events(irAEs),clinical efficacy,hospitalization-related costs,and satisfaction of medical staff and patients were compared between the two groups.Results The overall incidence of irAEs and the objective response rate between the control group and the observation group were comparable(40.00%vs.34.11%,18.82%vs.28.24%,P>0.05),while,the disease control rate in the observation group was significantly higher than that in the control group(87.06%vs.72.94%,P<0.05).There were no significant differences in total hospitalization costs,total drug costs,and ICIs costs between the two groups(P>0.05).The patients'satisfaction score in the observation group was significantly higher than that in the control group[(8.80±0.69)points vs.(8.21±0.34)points,P<0.05].Conclusion The participating of oncology clinical pharmacists in the full-process pharmaceutical care for ICIs is conducive to gradually standardizing the use of ICIs and ensuring that patients receive safe,effective,and economical therapeutic effects.关键词
免疫检查点抑制剂/肿瘤临床药师/全流程药学服务Key words
immune checkpoint inhibitor/oncology clinical pharmacist/full-process pharmaceutical care分类
医药卫生引用本文复制引用
任文艳,唐春梅,蒋心瑞,胡晓燕,唐志勇,杨思芸..肿瘤临床药师参与免疫检查点抑制剂全流程药学服务实践[J].中国药业,2026,35(6):34-37,4.基金项目
四川省南充市科技项目(市校科技战略合作专项)[22SXQT0358,22SXQT0015]. （市校科技战略合作专项）
